Table Graph
   

lopinavir/ritonavir - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 1.09 [0.99, 1.20]< 10%1 study (1/-)4.0 %NAnot evaluable crucial-
deaths 0.98 [0.88, 1.09]< 16%4 studies (4/-)66.7 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.83 [0.65, 1.06]< 10%1 study (1/-)92.9 %NAnot evaluable crucial-
clinical deterioration 3.69 [0.37, 36.57]< 10%1 study (1/-)13.4 %NAnot evaluable important-
clinical improvement 1.31 [0.94, 1.83]> 10%1 study (1/-)94.4 %NAnot evaluable important-
clinical improvement (14-day) 1.23 [0.55, 2.76]> 184%2 studies (2/-)69.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.59 [0.84, 3.03]> 10%1 study (1/-)92.1 %NAnot evaluable important-
clinical improvement (7-day) 3.16 [0.62, 16.06]> 10%1 study (1/-)91.7 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.31 [0.94, 1.83]> 10%1 study (1/-)94.4 %NAnot evaluable important-
hospital discharge 0.92 [0.79, 1.08]> 162%2 studies (2/-)15.9 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 0.48 [0.02, 11.28]> 10%1 study (1/-)32.8 %NAnot evaluable important-
radiologic improvement (7-day) 0.10 [0.00, 2.09]> 10%1 study (1/-)7.2 %NAnot evaluable important-
viral clearance 1.28 [0.19, 8.76]> 10%1 study (1/-)59.9 %NAnot evaluable important-
viral clearance by day 14 1.28 [0.19, 8.76]> 10%1 study (1/-)59.9 %NAnot evaluable important-
viral clearance by day 7 0.30 [0.05, 1.91]> 10%1 study (1/-)10.3 %NAnot evaluable important-

safety endpoints 00

serious adverse events 0.88 [0.30, 2.58]< 177%2 studies (2/-)59.0 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons